… there is currently no treatment,” said Dr. Bart Leroy, Head of the Ophthalmology Department and Professor of … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …
… Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p